Results 151 to 160 of about 8,066,649 (187)
Pathology of Resolving Polyomavirus-Associated Nephropathy [PDF]
American Journal of Transplantation, 2013 Control of polyomavirus BK (BKV) is achieved by reducing immunosuppression allowing an effective BKV-specific T-cell response. The morphology of resolving BKV-associated nephropathy (PyVAN) has not been systematically investigated. Ninety-nine surveillance biopsies of 35 patients with BKV viremia treated exclusively by immunosuppression reduction were ...
Stefan Schaub, Hans H Hirsch, H H Hirsch
exaly +9 more sources
A Mouse Model for Polyomavirus-Associated Nephropathy of Kidney Transplants [PDF]
American Journal of Transplantation, 2006 Polyomavirus-associated nephropathy is an important cause of dysfunction and failure of renal transplants. BK virus is an ubiquitous human polyoma virus that persistently infects the kidney. This otherwise silent infection can reactivate in immunosuppressed individuals, resulting in renal complications.
Christian Larsen +2 more
exaly +3 more sources
Journal of Clinical Virology, 2016 BK polyomavirus (BKPyV) commonly reactivates after kidney transplantation, and can cause polyomavirus-associated nephropathy (PyVAN), whereas after allogeneic stem cell transplantation the most frequent manifestation of BKPyV is polyomavirus-associated ...
Eeva Auvinen +2 more
exaly +2 more sources
American Journal of Kidney Diseases, 2001 Diagnosis of polyomavirus BK nephropathy and treatment by low-dose immunosuppression may be optimized by using surrogate markers, such as the detection of viral inclusion bearing cells in the urine and polyomavirus BK DNA in plasma by polymerase chain ...
Volker Nickeleit +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Polyomavirus-associated nephropathy: update on BK virus-specific immunity
Transplant Infectious Disease, 2006Abstract: The human polyomavirus type 1, also called BK virus (BKV), causes polyomavirus‐associated nephropathy (PVAN) in 1–10% of renal transplant recipients, with graft loss in over 50% of cases. The risk factors for PVAN are not conclusively defined and likely involve complementing determinants of recipient, graft, and virus.
Patrizia Comoli +2 more
exaly +3 more sources
Polyomavirus‐associated nephropathy: update on antiviral strategies
Transplant Infectious Disease, 2006Abstract: Polyomavirus‐associated nephropathy (PVAN) is a major complication of kidney transplantation. Many centers respond to PVAN by reducing immunosuppression. Concern over precipitating rejection, as well as situations in which some PVAN‐afflicted individuals have multi‐organ transplants, can make reduction of immunosuppression undesirable.
M A, Josephson +3 more
openaire +2 more sources
Granulomatous inflammation in
AbstractEvolving BK polyomavirus–associated nephropathy (BKPyVAN) is characterized by tubulointerstitial inflammation that closely resembles acute T‐cell–mediated allograft rejection if tubulitis is significant. The cellular composition of the inflammation varies during the course of BKPyVAN, and clusters of plasma cells may herald resolution of the ...
Yang Zhang +5 more
openaire +2 more sources
Primer: histopathology of polyomavirus-associated nephropathy in renal allografts
Nature Clinical Practice Nephrology, 2006The BK polyomavirus exhibits tropism for the renal tubular epithelium, where it establishes latent infection. Vigorous immunosuppression of renal allograft recipients can lead to reactivation of the infection and the development of polyomavirus-associated nephropathy (PVAN).
Peter, Liptak, Eva, Kemeny, Bela, Ivanyi
openaire +2 more sources